Dr. Badani on the Evolution of Robotic Retroperitoneal Partial Nephrectomies in RCC

In Partnership With:

Partner | Cancer Centers | <b>The Tisch Cancer Institute</b>

Ketan K. Badani, MD, discusses the evolution of robotic retroperitoneal partial nephrectomies in renal cell carcinoma.

Ketan K. Badani, MD, professor of urology, Icahn School of Medicine Mount Sinai, director, Robotic Surgery, Mount Sinai West, vice chairman, Urology and Robotic Operations, director, Comprehensive Kidney Cancer Program, Mount Sinai Health System, discusses the evolution of robotic retroperitoneal partial nephrectomies in renal cell carcinoma (RCC).

Retroperitoneal robotic surgery has long been a topic of discussion in the treatment landscape of RCC, Badani says. However, the evolution of the technology has made a substantial difference compared with tools used to conduct robotic surgery 20 years ago, Badani explains. The current system, the da Vinci XI, and the newest system, the da Vinci SP, allow clinicians to comfortably maneuver all the machine’s arms into the surgical space to conduct a more reliable and reproducible retroperitoneal operation, Badani says.

Older systems made the surgery much more cumbersome, and the new technology has made it easier to integrate these procedures back into practice, Badani concludes.